Please select the option that best describes you:

How does neoadjuvant chemo-immunotherapy impact your decision on hypofractionation/dose fractionation for locally advanced NSCLC, now getting RT alone?  

Is 60 Gy/15 fx appropriate? Is there a volume PTV cut-off (cc) which would switch to a more fractionated approach (e.g., 60 Gy/30 fx)? Is there an area you would dose reduce (e.g., hilum or mediastinum) after neoadjuvant chemo-immunotherapy?



Answer from: Radiation Oncologist at Community Practice
Sign in or Register to read more

Answer from: Radiation Oncologist at Academic Institution
Sign in or Register to read more